Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,118 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis, NOS Clear all
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

NCT02093026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisolone, Folic Acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 3 Interventional Results available

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501, US-licensed Humira®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
63
States / cities
Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Sep 30, 2026, 8:48 PM EDT
Terminated Phase 2 Interventional Results available

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

NCT00583557
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
belimumab
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

NCT01626573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Itacitinib, Itacitinib Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 3 Interventional Results available

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
pioglitazone, Sublingual nitroglycerine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The ArthritisPower Wearable Study

NCT05603806
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

NCT01011959
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Santa Maria, California • Boca Raton, Florida • Clearwater, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

NCT01725230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Rosuvastatin, Simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional

The Study of Abatacept in Combination With Etanercept

NCT00162279
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
35
States / cities
Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

NCT05858788
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 3 Interventional

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

NCT00042068
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Meloxicam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
72
States / cities
Huntsville, Alabama • Montgomery, Alabama • Anchorage, Alaska + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Completed No phase listed Observational Results available

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

NCT05576051
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
patterns of use of combination therapy and monotherapy
Other
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
9,159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 30, 2026, 8:48 PM EDT
Active, not recruiting No phase listed Observational

Discovering the Antecedents of Rheumatoid Arthritis Flare

NCT02051114
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 30, 2026, 8:48 PM EDT
Not listed No phase listed Observational

Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology

NCT03459274
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis
Interventions
VR-Biofeedback
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 30, 2026, 8:48 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 8:48 PM EDT
Suspended No phase listed Observational

Sjogren's Lung Study

NCT04843345
View directory record Official record
Conditions
Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 30, 2026, 8:48 PM EDT
Withdrawn Phase 4 Interventional

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

NCT01009879
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 30, 2026, 8:48 PM EDT
Active, not recruiting Not applicable Interventional

Persona Ti-Nidium Post-Market Clinical Follow-up

NCT04817969
View directory record Official record
Conditions
Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of the Knee, Avascular Necrosis, Patellofemoral Osteoarthritis
Interventions
Zimmer Biomet Persona Ti-Nidium Total Knee System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
7
States / cities
Parker, Colorado • Hyattsville, Maryland • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 8:48 PM EDT
Completed No phase listed Observational Results available

A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day

NCT04267380
View directory record Official record
Conditions
Arthritis Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 30, 2026, 8:48 PM EDT
Completed Not applicable Interventional Results available

Meditation Effects on Brain Function in Rheumatoid Arthritis

NCT03975595
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Meditation Intervention A, Meditation Intervention B
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
30 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 30, 2026, 8:48 PM EDT
Not listed Not applicable Interventional

Novel Splinting Technique Using 3D Models

NCT05351060
View directory record Official record
Conditions
Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions
Custom Fabricated Splint
Other
Lead sponsor
Giovanna Fichera
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 30, 2026, 8:48 PM EDT